Meanwhile,
Fluad vaccine available france:
Fluad obtained its European marketing authorization (AMM) in November 2024. Similarly, Already distributed at more than 110 million doses worldwide during the 2023-2024 season (United States, Australia, United Kingdom, etc.), it was until then not marketed in France. However, This vaccine is indicated in adults aged 50. Therefore, over, but the HAS recommends using it in priority in people 65 and over. Therefore, This recommendation was supplemented by a publication in the Official Journal of July 23, 2025.
COSTABLE IN ONFICINE – Fluad vaccine available france
According to the laboratory, Fluad is already available when ordering in pharmacies. Moreover, The pharmacies can place an order via:
- The network of medical promotion attached (APMS) of CSL Seqirus
- Customer service on 01 72 95 00 72.
The laboratory does not yet specify the volume of doses provided for France. In addition, but claims to be ” in working order to meet the needs expressed by pharmacies fluad vaccine available france ». This season should mark the strong introduction of improved vaccines in the vaccination strategy for over 65. which could contribute to an increase in vaccination coverage in this vulnerable population. The laboratory indicates working in close connection with the health authorities. which he considers ” the only ones to have an overview of the necessary volumes ».
CSL Seqirus also wishes to strengthen communication with pharmacists. via digital supports, the specialized press, and especially by proximity to its APMS teams, in direct contact with pharmacies for ” Understand and meet their needs ».
Note that in France, it is Vifor France who is the official operator of the antigrippaux vaccines of Seqirus Netherlands.
Competition with Sanofi – Fluad vaccine available france
The arrival of Fluad coincides with the return to the Efluelda market. the improved Sanofi vaccine, previously removed due to tariff disagreements.
The two vaccines are recommended by the HAS in the same target: adults 65 and fluad vaccine available france over. On the medico-economic level. they present a significant medical service (SMR) and an improvement in the minor SMR (ASMR IV) compared to the standard vaccines used against seasonal flu.
The CSL Seqirus laboratory highlights a specific asset of its product: “Fluad is distinguished from standard inactivated vaccines because it contains the adjuvant MF59. designed to increase and prolong the duration of the immune response, without having to increase the amount of antigens. »»
Price and refund
The Official Journal of July 23 set at 23.97 euros including tax the public price of a pre -filled syringe of Fluad.
Unlike Sanofi. who had encountered difficulties in obtaining an acceptable price, CSL Seqirus is satisfied with this rate, affirming that it reflects “its therapeutic value, and is coherent with the recognition of its clinical benefit, especially in the elderly, by the health authorities”. The laboratory stresses that the two vaccines were “valued at the fluad vaccine available france same level. which shows the consistency of the health authorities in this area”.
Fluad is 100 % reimbursed for people targeted by vaccination recommendations via a health insurance care voucher. Outside this framework, the reimbursement rate is 65 %.
Target 75 % vaccination coverage
Even if vaccine volumes should be sufficient for this 2025-2026 season. the vaccination coverage target set by the World Health Organization at 75 % among risky populations remains difficult to reach. The previous season was marked by a coverage of only 53.7 % among 65 years old and over, a slightly decreased figure.
Further reading: Faced with the resurgence of measles, an Albertan college innovates – A study suggests that vitamin D could cure breast cancer – More uses than expected for a Quebec cancer detection tool – research issues to deliver dopamine otherwise – validated by science, this vegetable oil acts as a good repulsive.